125 results
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
of the United States, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes
S-3ASR
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
, and obligations set forth in the RIPA and related transaction documents;
our expectations regarding the potential benefits of our strategy and technology … ;
our expectations regarding the operation and effectiveness of our product candidates and related benefits;
our ability to utilize multiple modes
S-3ASR
EX-4.3
cme73jy
17 Apr 24
Automatic shelf registration
5:24pm
S-3ASR
EX-5.1
qujh3q88k2glte19
17 Apr 24
Automatic shelf registration
5:24pm
424B5
42iytamb hodq
24 Jul 23
Prospectus supplement for primary offering
5:12pm
8-K
EX-1.1
2pvfq u8ev3bq91
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am